Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BHUPENDRA O KHATRI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1013982594
CMS profile
273219
Location
MILWAUKEE, WI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$174,720.56

128 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BHUPENDRA O KHATRI

NPI 1013982594 · CMS profile ID 273219

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

MILWAUKEE, WI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1013982594?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BHUPENDRA O KHATRI, NPI 1013982594, CMS profile ID 273219. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1013982594?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). BHUPENDRA O KHATRI, NPI 1013982594, CMS profile ID 273219. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1013982594?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
BHUPENDRA O KHATRI, NPI 1013982594, CMS profile ID 273219, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–128 of 128 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1013982594?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

128 matching records · $174,720.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 128 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–128 of 128.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $65.9704/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849174459 CMS
Janssen Pharmaceuticals, Inc $1,500.0004/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788940635 CMS
Biogen, Inc. $3,013.0004/16/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827827599 CMS
Celgene Corporation $3,410.0004/15/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783680165 CMS
Horizon Therapeutics plc $123.1904/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 797158241 CMS
Celgene Corporation $2,170.0004/13/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783680161 CMS
EMD Serono, Inc. $1,540.0004/09/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849180253 CMS
Alexion Pharmaceuticals, Inc. $2,295.0004/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783109549 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,360.0004/01/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820017085 CMS
Alexion Pharmaceuticals, Inc. $125.0003/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783109547 CMS
Celgene Corporation $300.0003/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783680183 CMS
Genentech USA, Inc. $1,800.0003/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835892483 CMS
Alexion Pharmaceuticals, Inc. $4,080.0003/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783109541 CMS
Alexion Pharmaceuticals, Inc. $1,020.0003/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783109545 CMS
E.R. Squibb & Sons, L.L.C. $4.3903/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783445141 CMS
E.R. Squibb & Sons, L.L.C. $4.3903/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783445139 CMS
Biogen, Inc. $1,695.0003/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827827601 CMS
GENZYME CORPORATION $4,585.0002/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843407277 CMS
GENZYME CORPORATION $1,911.0002/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843407217 CMS
GENZYME CORPORATION $2,184.0002/17/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843407215 CMS
Biogen, Inc. $1,130.0002/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827827579 CMS
Biogen, Inc. $1,695.0002/08/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827827577 CMS
Celgene Corporation $1,550.0002/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783680159 CMS
Celgene Corporation $1,550.0001/28/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783680163 CMS
Novartis Pharmaceuticals Corporation $24.5701/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812749533 CMS
Biogen, Inc. $1,695.0001/27/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827827575 CMS
Biogen, Inc. $1,695.0001/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827827573 CMS
Biogen, Inc. $22.5401/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827827589 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $832,629.96 540
PY2020 $286,859.03 211
PY2021 $174,720.56 128
PY2022 $308,797.49 222
PY2023 $345,003.33 228
PY2024 $285,334.62 179
PY2025 $220,335.46 123

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,514.62 2
PY2025 Principal investigator $831,489.55 156
PY2024 Principal investigator $842,774.79 90
PY2023 Principal investigator $537,221.80 112
PY2022 Recipient $92,210.00 1
PY2022 Principal investigator $818,481.21 173
PY2021 Recipient $67,208.75 1
PY2021 Principal investigator $729,447.97 151
PY2020 Recipient $54,727.65 12
PY2020 Principal investigator $591,243.70 65
PY2019 Recipient $10,880.49 13
PY2019 Principal investigator $450,873.80 73

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

158 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 EMD Serono, Inc. $1,000.00 12/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118585
Principal investigator 1 EMD Serono, Inc. $350.00 12/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118591
Principal investigator 1 Roche Products Limited $329.00 12/22/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685312
Principal investigator 1 Genentech, Inc. $2,441.00 12/19/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685368
Principal investigator 1 Roche Products Limited $329.00 12/17/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685304
Principal investigator 1 Roche Products Limited $329.00 12/17/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685306
Principal investigator 1 Roche Products Limited $329.00 12/17/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685308
Principal investigator 1 Roche Products Limited $329.00 12/17/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685310
Principal investigator 1 Genentech, Inc. $2,120.00 12/05/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685364
Principal investigator 1 Genentech, Inc. $450.00 12/04/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685246
Principal investigator 1 Janssen Research & Development, LLC $1,360.00 12/02/2025 Non-covered Recipient Entity
Bcn Rsrch Llc
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175299816
Principal investigator 1 Genentech, Inc. $2,400.00 12/01/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685366
Principal investigator 1 Novartis Pharmaceuticals Corporation $60.00 12/01/2025 Non-covered Recipient Entity
WHEATON FRANCISCAN HEALTH CARE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307637
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,336.48 12/01/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGICAL DISORDERS G
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase No dispute reported 06/30/2026 1190312815
Principal investigator 1 Genentech, Inc. $2,441.00 11/25/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685360
Principal investigator 1 Genentech, Inc. $120.00 11/21/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685362
Principal investigator 1 Genentech, Inc. $4,815.00 11/20/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685352
Principal investigator 1 Genentech, Inc. $52.00 11/20/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685356
Principal investigator 1 Genentech, Inc. $52.00 11/20/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685358
Principal investigator 1 GENZYME CORPORATION $5,340.00 11/17/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138773
Principal investigator 1 GENZYME CORPORATION $11,525.60 11/17/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138777
Principal investigator 1 Genentech, Inc. $4,815.00 11/17/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685354
Principal investigator 1 Genentech, Inc. $2,350.00 11/14/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685344
Principal investigator 1 Genentech, Inc. $4,800.00 11/14/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685346
Principal investigator 1 Genentech, Inc. $1,350.00 11/07/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685230
Principal investigator 1 Genentech, Inc. $1,416.00 11/06/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211685322
Principal investigator 1 Genentech, Inc. $4,815.00 11/05/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685348
Principal investigator 1 Genentech, Inc. $52.00 11/05/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685350
Principal investigator 1 Genentech, Inc. $1,000.00 11/03/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685226
Principal investigator 1 Genentech, Inc. $300.00 11/03/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685228
Principal investigator 1 Genentech, Inc. $350.00 11/03/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685232
Principal investigator 1 Genentech, Inc. $1,100.00 11/03/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685234
Principal investigator 1 Genentech, Inc. $500.00 11/03/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685236
Principal investigator 1 Genentech, Inc. $7,700.00 11/03/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685238
Principal investigator 1 Genentech, Inc. $1,750.00 11/03/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685240
Principal investigator 1 Genentech, Inc. $350.00 11/03/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685242
Principal investigator 1 Genentech, Inc. $500.00 11/03/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685244
Principal investigator 1 Janssen Research & Development, LLC $6,184.00 10/29/2025 Non-covered Recipient Entity
Bcn Rsrch Llc
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175299763
Principal investigator 1 Novartis Pharmaceuticals Corporation $214.08 10/28/2025 Covered Recipient Teaching Hospital
Ascension St. Francis Hospital
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190298171
Principal investigator 1 Novartis Pharmaceuticals Corporation $29,536.14 10/27/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGICAL DISORDERS G
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Remibrutinib in Patients With Generalized Myasthenia Gravis, Followed by an Open-label Extension Phase No dispute reported 06/30/2026 1190312817
Principal investigator 1 EMD Serono, Inc. $1,750.00 10/22/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118581
Principal investigator 1 EMD Serono, Inc. $175.00 10/22/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118583
Principal investigator 1 EMD Serono, Inc. $650.00 10/22/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118587
Principal investigator 1 EMD Serono, Inc. $350.00 10/22/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational evaluation of Effectiveness And Patient-Reported outcomes (PROs) in suboptimally controlled patients previously taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1240118589
Recipient F. Hoffmann-La Roche AG $424.06 10/03/2025 Covered Recipient Physician Associations between comorbidities, disease activity and response to ocrelizumab in the CHIMES trial No dispute reported 06/30/2026 1211534869
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $17,500.00 10/03/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223286273
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,120.00 10/03/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223286275
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,052.00 10/03/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223286277
Recipient F. Hoffmann-La Roche AG $1,090.56 10/02/2025 Covered Recipient Physician Efficacy Tolerability of Ocrelizumab in African Americans Hispanic Americans vs Caucasians No dispute reported 06/30/2026 1211534872
Principal investigator 1 TG Therapeutics, Inc. $270.00 09/30/2025 Non-covered Recipient Entity
BCN Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200737
Principal investigator 1 GENZYME CORPORATION $5,285.00 09/29/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138766
Principal investigator 1 Roche Products Limited $329.00 09/25/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685282
Principal investigator 1 Roche Products Limited $329.00 09/25/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685284
Principal investigator 1 Roche Products Limited $329.00 09/25/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685286
Principal investigator 1 Roche Products Limited $329.00 09/25/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685292
Principal investigator 1 Roche Products Limited $329.00 09/25/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685294
Principal investigator 1 Roche Products Limited $329.00 09/25/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685296
Principal investigator 1 Roche Products Limited $329.00 09/25/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685298
Principal investigator 1 Genentech, Inc. $16,131.95 09/19/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685224
Principal investigator 1 Janssen Research & Development, LLC $6,468.00 09/19/2025 Non-covered Recipient Entity
Bcn Rsrch Llc
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175299825
Principal investigator 1 Genentech, Inc. $2,123.00 09/18/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211685320
Principal investigator 1 Genentech, Inc. $829.00 09/17/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685342
Principal investigator 1 TG Therapeutics, Inc. $2,970.00 08/31/2025 Non-covered Recipient Entity
BCN Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200741
Principal investigator 1 Janssen Research & Development, LLC $9,632.00 08/28/2025 Non-covered Recipient Entity
Bcn Rsrch Llc
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175299799
Principal investigator 1 GENZYME CORPORATION $3,092.60 08/04/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138827
Principal investigator 1 GENZYME CORPORATION $3,092.60 08/04/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138832
Principal investigator 1 TG Therapeutics, Inc. $2,902.50 07/31/2025 Non-covered Recipient Entity
BCN Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200739
Principal investigator 1 Janssen Research & Development, LLC $10,589.00 07/18/2025 Non-covered Recipient Entity
Bcn Rsrch Llc
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175299775
Principal investigator 1 Genentech, Inc. $350.00 07/10/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685202
Principal investigator 1 Genentech, Inc. $344.50 07/10/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685210
Principal investigator 1 Genentech, Inc. $1,000.00 07/10/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685212
Principal investigator 1 Genentech, Inc. $942.00 07/10/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685214
Principal investigator 1 Genentech, Inc. $4,815.00 07/10/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685220
Principal investigator 1 Roche Products Limited $350.00 07/10/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685288
Principal investigator 1 Roche Products Limited $1,750.00 07/10/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685290
Principal investigator 1 Roche Products Limited $1,355.20 07/08/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685300
Principal investigator 1 Roche Products Limited $350.00 07/08/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685302
Principal investigator 1 Genentech, Inc. $160.00 07/07/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685200
Principal investigator 1 Genentech, Inc. $1,000.00 07/07/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685204
Principal investigator 1 Genentech, Inc. $1,000.00 07/07/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685206
Principal investigator 1 Genentech, Inc. $470.70 07/07/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685208
Principal investigator 1 Genentech, Inc. $350.00 07/07/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685216
Principal investigator 1 Genentech, Inc. $160.00 07/07/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685218
Principal investigator 1 Genentech, Inc. $350.00 07/07/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685222
Principal investigator 1 GENZYME CORPORATION $4,347.00 07/02/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138823
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 07/01/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGICAL DISORDERS
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223281930
Principal investigator 1 Genentech, Inc. $108.00 06/26/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685192
Principal investigator 1 Genentech, Inc. $1,050.00 06/26/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685198
Principal investigator 1 Janssen Research & Development, LLC $11,274.00 06/26/2025 Non-covered Recipient Entity
Bcn Rsrch Llc
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175299782
Principal investigator 1 Roche Products Limited $329.00 06/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685270
Principal investigator 1 Roche Products Limited $329.00 06/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685272
Principal investigator 1 Roche Products Limited $329.00 06/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685274
Principal investigator 1 Roche Products Limited $329.00 06/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685276
Principal investigator 1 Roche Products Limited $329.00 06/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685278
Principal investigator 1 Roche Products Limited $329.00 06/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685280
Principal investigator 1 Genentech, Inc. $1,000.00 06/19/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685188
Principal investigator 1 Genentech, Inc. $350.00 06/19/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685190
Principal investigator 1 Janssen Research & Development, LLC $8,650.00 06/06/2025 Non-covered Recipient Entity
Bcn Rsrch Llc
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175299769
Principal investigator 1 TG Therapeutics, Inc. $6,904.59 06/01/2025 Non-covered Recipient Entity
BCN Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200711
Principal investigator 1 Genentech, Inc. $3,300.00 05/28/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211685314
Principal investigator 1 Genentech, Inc. $1,200.00 05/28/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211685316
Principal investigator 1 Genentech, Inc. $68.00 05/28/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685326
Principal investigator 1 GENZYME CORPORATION $2,100.00 05/27/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226138801
Principal investigator 1 GENZYME CORPORATION $1,350.00 05/27/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226138806
Principal investigator 1 GENZYME CORPORATION $1,350.00 05/27/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing SAR442168 to Placebo in Participants With Primary Progressive Multiple Sclerosis (PERSEUS) No dispute reported 06/30/2026 1226138810
Principal investigator 1 Genentech, Inc. $120.00 05/23/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685324
Principal investigator 1 GENZYME CORPORATION $6,239.40 05/19/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138818
Principal investigator 1 GENZYME CORPORATION $23,500.00 05/12/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) No dispute reported 06/30/2026 1226138814
Principal investigator 1 Genentech, Inc. $1,007.00 05/07/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685340
Principal investigator 1 Genentech, Inc. $68.00 05/02/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685336
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,312.00 05/01/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223278734
Principal investigator 1 Genentech, Inc. $1,050.00 04/30/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685186
Principal investigator 1 Genentech, Inc. $764.00 04/30/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685194
Principal investigator 1 Genentech, Inc. $998.00 04/30/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685196
Principal investigator 1 Janssen Research & Development, LLC $7,440.00 04/28/2025 Non-covered Recipient Entity
Bcn Rsrch Llc
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175299809
Principal investigator 1 Genentech, Inc. $9,649.00 04/15/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Ocrelizumab PPMS High Dose Study No dispute reported 06/30/2026 1211685318
Principal investigator 1 Hoffmann-La Roche Limited $650.00 04/11/2025 Non-covered Recipient Entity
WHEATON FRANCISCAN HEALTHCARE
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211685182
Principal investigator 1 Hoffmann-La Roche Limited $1,000.00 04/09/2025 Non-covered Recipient Entity
WHEATON FRANCISCAN HEALTHCARE
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211685176
Principal investigator 1 Hoffmann-La Roche Limited $3,450.00 04/09/2025 Non-covered Recipient Entity
WHEATON FRANCISCAN HEALTHCARE
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211685178
Principal investigator 1 Hoffmann-La Roche Limited $260.00 04/09/2025 Non-covered Recipient Entity
WHEATON FRANCISCAN HEALTHCARE
Study of ocrelizumab in PPMS patients assessing upper limb function No dispute reported 06/30/2026 1211685180
Principal investigator 1 GENZYME CORPORATION $5,508.70 04/02/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138798
Principal investigator 1 Genentech, Inc. $52.00 04/02/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685334
Principal investigator 1 Genentech, Inc. $6,825.00 04/02/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685338
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,312.00 04/01/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223277191
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $159.00 04/01/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223277195
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $135.00 04/01/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) No dispute reported 06/30/2026 1223277204
Principal investigator 1 TG Therapeutics, Inc. $6,811.88 03/31/2025 Non-covered Recipient Entity
BCN Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200713
Principal investigator 1 Janssen Research & Development, LLC $16,009.00 03/25/2025 Non-covered Recipient Entity
Bcn Rsrch Llc
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175299755
Principal investigator 1 Roche Products Limited $329.00 03/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685248
Principal investigator 1 Roche Products Limited $329.00 03/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685252
Principal investigator 1 Roche Products Limited $329.00 03/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685254
Principal investigator 1 Roche Products Limited $329.00 03/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685256
Principal investigator 1 Roche Products Limited $329.00 03/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685266
Principal investigator 1 Roche Products Limited $329.00 03/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685268
Principal investigator 1 GENZYME CORPORATION $11,525.60 03/17/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare Southeast Wisconsin Inc
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226138793
Principal investigator 1 Genentech, Inc. $1,615.00 03/05/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab No dispute reported 06/30/2026 1211685184
Principal investigator 1 TG Therapeutics, Inc. $2,497.50 02/28/2025 Non-covered Recipient Entity
BCN Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200715
Principal investigator 1 Roche Products Limited $246.75 02/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685250
Principal investigator 1 Roche Products Limited $329.00 02/24/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685258
Principal investigator 1 Genentech, Inc. $52.00 02/20/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685332
Principal investigator 1 Alexion Pharmaceuticals, Inc. $2,073.94 02/07/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
A Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate the Efficacy and Safety of ALXN2050 in Adult Participants with Generalized Myasthe No dispute reported 06/30/2026 1185549635
Principal investigator 1 UCB SA $38,918.98 02/07/2025 Non-covered Recipient Entity
Wheaton Franciscan Healthcare - Southeast Wisconsin, Inc.
Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis No dispute reported 06/30/2026 1246657414
Principal investigator 1 TG Therapeutics, Inc. $14,892.19 02/01/2025 Non-covered Recipient Entity
BCN Research, LLC
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226200717
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,213.79 01/31/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGICAL DISORDERS G
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190312819
Principal investigator 1 Genentech, Inc. $10,250.00 01/29/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
Ocrevus Subcutaneous Study for Safety and Tolerability No dispute reported 06/30/2026 1211578388
Principal investigator 1 Alexion Pharmaceuticals, Inc. $731.70 01/22/2025 Non-covered Recipient Entity
WHEATON FRANCISCAN HEALTHCARE
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) No dispute reported 06/30/2026 1185549639
Principal investigator 1 Genentech, Inc. $52.00 01/13/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685328
Principal investigator 1 Alexion Pharmaceuticals, Inc. $14,142.05 01/09/2025 Non-covered Recipient Entity
WHEATON FRANCISCAN HEALTHCARE
Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies No dispute reported 06/30/2026 1185549637
Principal investigator 1 Novartis Pharmaceuticals Corporation $33,597.52 01/09/2025 Non-covered Recipient Entity
ASCENSION ST FRANCIS CENTER
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190310004
Principal investigator 1 Roche Products Limited $329.00 01/09/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685260
Principal investigator 1 Roche Products Limited $329.00 01/09/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685262
Principal investigator 1 Roche Products Limited $329.00 01/09/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211685264
Principal investigator 1 Genentech, Inc. $4,815.00 01/08/2025 Non-covered Recipient Entity
WHEATON FRANCSICAN HEALTHCARE-SOUTHEAST WISCONSIN INC
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211685330
Principal investigator 1 UCB SA $28,785.80 01/08/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
A PHASE 3B, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ZILUCOPLAN IN PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS SWITCHING FROM INTRAVENOUS COMPLEMENT COMPONENT 5 INHIBITORS TO SUBCUTANEOUS ZILUCOPLAN No dispute reported 06/30/2026 1246656957
Principal investigator 1 UCB SA $8,614.00 01/07/2025 Non-covered Recipient Entity
BCN RESEARCH LLC
A MULTICENTER, OPEN-LABEL, outpatient STUDY TO EVALUATE THE SAFE AND EFFECTIVE USE OF A ZILUCOPLAN AUTO?INJECTOR COMBINATION PRODUCT FOR SUBCUTANEOUS SELF-ADMINISTRATION BY STUDY PARTICIPANTS WITH GENERALIZED MYASTHENIA GRAVIS No dispute reported 06/30/2026 1246656231
Principal investigator 1 Janssen Research & Development, LLC $5,843.00 01/03/2025 Non-covered Recipient Entity
Bcn Rsrch Llc
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) No dispute reported 06/30/2026 1175299791
Principal investigator 1 Novartis Pharmaceuticals Corporation $293,060.81 01/01/2025 Non-covered Recipient Entity
WHEATON FRANCISCAN HEALTH CARE
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190307639
Principal investigator 1 Novartis Pharmaceuticals Corporation $168.00 01/01/2025 Non-covered Recipient Entity
ASCENSION ST FRANCIS CENTER
A Single-arm, Prospective, Multicentre, Open-label Study to Evaluate Ofatumumab Treatment Effectiveness and Patient Reported Outcomes in Patients With Relapsing Multiple Sclerosis Transitioning From Dimethyl Fumarate or Fingolimod Therapy No dispute reported 06/30/2026 1190310006